Medications

US Pfizer, India's Biocon scrap insulin pact

India's largest biotechnology firm, Biocon, and US pharmaceutical giant Pfizer said Tuesday they would scrap a joint plan to sell insulin products, sending Biocon's shares plunging.

Health

Medical workforce data shortage hampering access to care

Challenges with data collection and infrastructure are affecting medical workforce research and access to medical care, particularly in rural and regional Australia, according to the authors of a Perspective published by ...

Medications

US drug firm Mylan to buy Indian firm for $1.6 bn

US generic drugs specialist Mylan said Thursday it would buy a unit of India's pharma firm Strides Arcolab for $1.6 billion, boosting its presence in the high-growth injectable drugs market.

Other

GlaxoSmithKline says Q3 net profits drop 18.5%

British drugmaker GlaxoSmithKline said Wednesday that third-quarter net profits fell 18.5 percent from a year earlier to £1.12 billion ($1.80 billion, 1.39 billion euros), hit by weak conditions in Europe.

Other

Pfizer 3Q profit falls 14 pct on generic Lipitor (Update)

(AP)—Drug giant Pfizer Inc. said Thursday that its third-quarter profit fell 14 percent as sales plunged, mainly due to U.S. generic competition to cholesterol fighter Lipitor, long the world's top-selling drug.

Other

Valeant to buy Bausch + Lomb for $8.7B (Update)

Canadian drugmaker Valeant Pharmaceuticals said Monday that it will pay $8.7 billion to buy Bausch + Lomb, one of the world's best-known makers of contact lenses, in a massive expansion of Valeant's smaller ophthalmology ...

page 2 from 3